83 studies found for:
"Fabry disease"
| Rank | Status | Study | ||||
|---|---|---|---|---|---|---|
| 21 | Completed |
Study to Collect Data on Fabry Disease Patients With Enhanceable Alpha-Galactosidase A Activity
|
||||
| 22 | Recruiting |
Immune Response in Subjects With Fabry Disease Who Are Switching From Agalsidase Alfa to Agalsidase Beta
|
||||
| 23 | Active, not recruiting |
Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease
|
||||
| 24 | Recruiting |
Canadian Fabry Disease Initiative (CFDI) Enzyme Replacement Therapy (ERT) Study
|
||||
| 25 | Recruiting |
Sophisticated Assessment of Disease Burden in Patients With Fabry Disease
|
||||
| 26 | Completed |
Vasodilation in Patients With Fabry's Disease
|
||||
| 27 | Not yet recruiting |
Myocardial Affectation in Patients With Fabry Disease Without Phenotypic Manifestation. Diagnostic Value of Biomarkers
|
||||
| 28 | Completed |
Neuropathic Pain and Fabry Disease
|
||||
| 29 | Recruiting |
Enzyme Replacement Therapy in Fabry Disease
|
||||
| 30 | Completed |
Anderson-Fabry Disease in Chronic Kidney Disease Patients Not on Renal Replacement Therapy
|
||||
| 31 | Completed |
Antiproteinuric Agents and Fabry Disease
|
||||
| 32 | Active, not recruiting |
Viennese Prevalence Study of Anderson-Fabry Disease
|
||||
| 33 |
Completed
Has Results |
A Study of Fabrazyme in Pediatric Patients With Fabry Disease
|
||||
| 34 | Available |
Treatment Protocol to Observe the Safety of Agalsidase Alfa in Canadian Patients With Fabry Disease
|
||||
| 35 | Completed |
An Open-Label Maintenance Study of the Enzyme Replacement Therapy Replagal in Patients With Fabry Disease
|
||||
| 36 | Completed |
A Study of AT1001 in Patients With Fabry Disease
|
||||
| 37 | No longer available |
Treatment Protocol of Replagal for Patients With Fabry Disease
|
||||
| 38 | Completed |
A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease
|
||||
| 39 | Enrolling by invitation |
Extension Study of TKT028 Evaluating Safety and Clinical Outcomes of Replagal® in Adult Patients With Fabry Disease
|
||||
| 40 | Unknown † |
Evaluation of Efficacy and Safety of Agalsidase Beta in Heterozygous Females for Fabry Disease
|
† Indicates status has not been verified in more than two years

